T-DXd rechallenge after grade 1 interstitial lung disease appears safe and clinically beneficial in a real-world setting
Breast Cancer
CHICAGO 2025
Related content
COMMENTED
Lung, Respiratory and Thoracic Cancer
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
Ann Oncol
Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA
doi: 10.1016/j.annonc.2025.07.015
Lung, Respiratory and Thoracic Cancer
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)
Lung Cancer
Borghetti P, D'Angelillo R, Facheris G, Borghesi A, Bruni A, Ceruti P, Ferrari K, Filippi AR, Ramella S, Signorelli D, Pappagallo G, Ricardi U, Collaborators
doi: 10.1016/j.lungcan.2025.108807
Lung, Respiratory and Thoracic Cancer
Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study
Oncol Ther
Godbert B, Gobbini E, Decroisette C, Lena H, Khalife Y, Brellier F, Fleuriet A, Zysman M, Egenod T, Moro Sibilot D, Girard N
doi: 10.1007/s40487-025-00381-z
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
ESMO 2025
Breast Cancer
LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease
SABCS 2025
Breast Cancer
Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease
Lung, Respiratory and Thoracic Cancer
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Lung Cancer
Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB
doi: 10.1016/j.lungcan.2024.108038
CHICAGO 2025
Genitourinary Cancer
Earlier initiation of 177Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting
Lymphoma